Where I see patients (1)
My reviews
Selected research
-
Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research
-
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.
Annals of oncology : official journal of the European Society for Medical Oncology
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Nature medicine
Clinical trials
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast C...
Objective response rate (ORR) is defined as the proportion of participants who experience complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The ORR and corresponding t...
Recruiting
5.0